Table 2.
Frequency of reported conditions for all women with a PM, those with FXPOI, and those without FXPOI, listed in order of frequency reported by all PM women.
| All PM (N = 355) | FXPOI (N = 87) | No FXPOI (N = 168) | P values for models comparing FXPOI and no FXPOIc | ||||||
|---|---|---|---|---|---|---|---|---|---|
| % Total | % Option 1a /% option 2b | % Total | % Option 1a /% option 2b | % Total | % Option 1a /% option 2b | Model 1: logistic regression | Model 2: logistic regression | Survival analysis | |
| Anxiety | 37.8% | 15.2% / 22.5% | 44.8% | 12.6% / 32.2% | 30.4% | 12.5% / 17.9% | 0.161 | 0.150 | 0.001 |
| Depression | 35.5% | 8.4% / 27.0% | 33.3% | 2.3% / 31.0% | 35.1% | 10.1% / 25.0% | 0.412 | 0.541 | 0.044 |
| Migraine headaches | 33.2% | 12.4% / 20.8% | 33.3% | 9.2% / 24.1% | 26.8% | 8.3% / 18.4% | 0.809 | 0.485 | 0.087 |
| Tension headaches | 31.5% | 21.7% / 9.9% | 31.0% | 17.2% / 13.8% | 28.6% | 22.0% / 6.5% | 0.671 | 0.098 | 0.026 |
| Sleep problems | 28.7% | 20.8% / 7.9% | 34.5% | 26.4% / 8.0% | 30.4% | 21.4% / 8.9% | 0.249 | 0.914 | 0.608 |
| Peripheral neuropathy | 20.3% | 14.7% / 5.6% | 22.1% | 16.3% / 5.8% | 21.4% | 14.3% / 7.1% | 0.802 | 0.811 | 0.899 |
| IBS | 19.7% | 8.2% / 11.5% | 19.5% | 6.9% / 12.6% | 17.9% | 8.3% / 9.5% | 0.613 | 0.710 | 0.201 |
| Osteoporosis | 19.1% | 1.4% / 17.7% | 26.4% | 0% / 26.4% | 20.8% | 1.8% / 19.0% | 0.017 | 0.056 | 0.001 |
| Hypothyroidism | 17.5% | 3.1% / 14.4% | 23.0% | 2.3% / 20.7% | 17.9% | 3.0% / 14.9% | 0.221 | 0.114 | 0.033 |
| Hypertension | 16.9% | 0.6% / 16.3% | 10.3% | 1.1% / 9.2% | 23.8% | 0% / 23.8% | 0.130 | 0.074 | 0.170 |
| RLS | 15.2% | 11.3% / 3.9% | 12.6% | 9.2% / 3.4% | 14.9% | 11.3% / 3.6% | 0.895 | 0.544 | 0.381 |
| Ataxia | 13.5% | 9.9% / 3.7% | 9.2% | 5.7% / 3.4% | 15.5% | 11.3% / 4.2% | 0.799 | 0.578 | 0.562 |
| Sleep apnea | 13.0% | 5.6% / 7.3% | 14.9% | 6.9% / 8.0% | 16.7% | 6.5% / 10.1% | 0.870 | 0.719 | 0.460 |
| Chronic muscle pain | 11.9% | 7.3% / 4.5% | 14.9% | 5.7% / 9.2% | 10.1% | 7.1% / 3.0% | 0.125 | 0.027 | 0.025 |
| Social phobia | 11.8% | 10.7% / 1.1% | 20.7% | 18.4% / 2.3% | 10.7% | 9.5% / 1.2% | 0.025 | 0.462 | 0.370 |
| Fibromyalgia | 11.5% | 4.5% / 7.0% | 16.1% | 3.4% / 12.6% | 9.5% | 4.8% / 4.8% | 0.100 | 0.019 | 0.005 |
| CFS | 11.3% | 9.0% / 2.2% | 14.9% | 11.5% / 3.4% | 8.3% | 6.5% / 1.8% | 0.083 | 0.382 | 0.201 |
| TMJ | 11.3% | 1.4% / 9.9% | 16.0% | 4.6% / 11.5% | 10.7% | 0% / 10.7% | 0.170 | 0.846 | 0.473 |
| OCD | 10.7% | 8.4% / 2.2% | 10.3% | 5.7% / 4.6% | 11.9% | 9.5% / 2.4% | 0.288 | 0.980 | 0.228 |
| ADHD | 10.7% | 7.6% / 3.1% | 12.6% | 10.3% / 2.3% | 10.1% | 6.5% / 3.6% | 0.974 | 0.289 | 0.736 |
| LD | 10.4% | 7.6% / 2.8% | 6.9% | 5.7% / 1.1% | 10.7% | 8.3% / 2.4% | 0.347 | 0.124 | 0.589 |
| Tremor | 10.1% | 7.0% / 3.1% | 8.0% | 5.7% / 2.3% | 11.9% | 8.3% / 3.6% | 0.811 | 0.823 | 0.806 |
Model 1: endorsement of either option 1 or option 2 was used to define affected individuals. Model 2: endorsement of option 2 only is used to define affected individuals. Endorsement of option 1 is grouped with option 0 as the unaffected population.
ADHD attention deficit–hyperactivity disorder, CFS chronic fatigue syndrome, IBS irritable bowel syndrome, LD learning disability, OCD obsessive compulsive disorder, RLS restless leg syndrome, TMJ temporomandibular joint dysfunction.
a% of subjects who selected “I think I have this but have not been diagnosed by a medical professional.”
b% of subjects who selected “I have been diagnosed with this by a medical professional.”
cBonferroni-adjusted statistical significance p < 0.002 are bolded; Marginally significant models where significance was between 0.001 and 0.05 are underlined.